LAS VEGAS /PRNewswire/ - GB Sciences, Inc. has signed a consulting services agreement with Worldwide Clinical Trials, Inc. to evaluate the company’s intellectual property portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. These pre-IND consulting services will be performed by the Chief Medical and Scientific Officer (CMSO) of Worldwide, Michael F. Murphy, MD, PhD, as the representative of an extended Worldwide team. Murphy has participated in the IND application process for multiple small molecules and biologics with 19 therapeutic targets, across five divisions of the FDA. Murphy was also the Clinical Research and Excellence (CARE) Lifetime Achievement Award recipient for 2017. The award is presented annually to an individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career.
According to Dr. Murphy, "Current research and development practices emphasize the importance of coordinated activity by industry, academia, and contract research organizations in the evaluation of innovative products, like those of GB Sciences. The process enhances program efficiency, facilitates the integration of the perspective of diverse stakeholders early in clinical development, and is a testament to GB Sciences’ strategic vision for the development of their portfolio of products. Worldwide is very pleased to be a contributor to that process, and the state-of-the-art technology which it reflects."
Growblox Life Sciences, LLC has filed three provisional patent applications to protect complex mixtures derived from the cannabis plant, which address twenty-six different disease-specific formulations within the company’s intellectual property portfolio. On April 21, 2017, the company held a Drug Development Strategy Meeting in Las Vegas, co-chaired by Dr. Murphy, and GB Sciences’ Chief Science Officer, Dr. Andrea Small-Howard. Reviewing the scientific validation and market factors related to the development of these twenty-six disease-specific formulations formed basis of the criteria for selecting three disease-specific formulations from the portfolio for further development by Growblox Life Sciences.
The Company will now focus its resources on the development of a) two formulations that will be prepared for pilot human studies in the Nevada market and b) one formulation that will be put through pre-clinical studies prior to an IND-filing for official FDA-registered clinical trials.
“We are honored to be working with Dr. Michael Murphy and the industry experts at Worldwide Clinical Trials to evaluate our portfolio and to create the pre-IND plan for the development of our cardiovascular therapies and to design our pilot studies for evaluating the effectiveness of both our Parkinson’s disease and chronic pain formulations,” said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com, http://gbsciences.com
Investors: John Poss, j.poss@gbsciences.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.